Join Dr. Kiri Granger, Director of Neuroscience, Cambridge Cognition and Dr. Steve Brannan, Chief Medical Officer, Karuna Pharmaceuticals Inc. for a live discussion on improving clinical trial success in schizophrenia.
The webinar takes place on Tuesday, January 30, 2018 at 11am EST (4pm GMT).
Clinical trials in schizophrenia have typically focused on addressing the positive symptoms of the disorder, such as hallucinations.
In contrast, cognitive impairment represents a significant, unaddressed therapeutic need. Indeed, cognitive impairment associated with schizophrenia (CIAS) is detrimental for patients’ both socially and occupationally, which has wider ramifications on the societal cost of the disorder.
Pharmaceutical companies have made considerable efforts to address CIAS. Nevertheless, no drugs have successfully made it through the development and approvals process.
In this webinar, Drs Granger and Brannan will lead an interactive session on why there have been so many late-stage failures in schizophrenia trials, and will suggest potential solutions to these problems.
Key discussion points
- Methods to improve patient recruitment and in-trial retention
- Key issues and considerations with the selection of endpoint measures in Schizophrenia trials
- Ways to accelerate decision making about safety and efficacy for CIAS treatments
- Lessons learned from successes and failures in clinical studies and regulatory considerations
